December 19, 2013
Essential Formulas Incorporated and BioBank Ltd. (Japan) announced the recent publication of an original research study on the “Safety and Tolerability of Dr. Ohhira’s OM-X Capsules in Healthy Volunteers.”
The high level of safety and tolerability of Dr. Ohhira’s was confirmed in a recent study published in the October 2013 issue of the Integrative Medicine (IMJC), Vol. 12, No 5. Authored by Egilius L. H. Spierings, MD, Thomas Walshe, MD, and Fred Pescatore, MD, the randomized, double blind, placebo-controlled trial was designed to the same standards used in pharmaceutical drug trials. The endpoints were established, adverse events were carefully monitored, and the subjects were carefully chosen to reduce variability. The trial conforms to a Phase I safety trial and the results are similar to those obtained in a previous unpublished trial of the Dr. Ohhira’s OM-X product, which was conducted outside of the United States.
The findings of the study were confirmed over a one-month period with the participation of fifty-one healthy men and woman who were given one (1) Dr. Ohhira’s probiotic capsule twice a day (2x) for 30 days. “The outcome of this study was no surprise as I have been recommending Dr. Ohhira’s Probiotics to my patients for years with exceptional clinical results,” said Fred Pescatore, MD, co-author of the study.
“Nearly 30 years of supporting science has earned Dr. Ohhira’s Probiotics® the respect of the scientific, academic, medical, and holistic health communities,” said Michael Schoor, President and CEO of Essential Formulas Incorporated.